NCT01943851 - A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

May 14, 2014

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions

Neoplasms

Interventions

DRUG

GSK525762

GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.

Trial Locations (15)

3002

GSK Investigational Site, East Melbourne

10065

GSK Investigational Site, New York

19104

GSK Investigational Site, Philadelphia

28006

GSK Investigational Site, Madrid

28040

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

37007

GSK Investigational Site, Salamanca

72205

GSK Investigational Site, Little Rock

77030

GSK Investigational Site, Houston

80045

GSK Investigational Site, Aurora

03722

GSK Investigational Site, Seoul

06351

GSK Investigational Site, Seoul

08036

GSK Investigational Site, Barcelona

CB2 0QQ

GSK Investigational Site, Cambridge

W12 0NN

GSK Investigational Site, London